Journal article

Bilateral facial nerve palsies due to leptomeningeal progression of lung adenocarcinoma and response to osimertinib

Matthew Durie, Mark Faragher

BMJ CASE REPORTS | BMJ PUBLISHING GROUP | Published : 2021

Abstract

A 39-year-old female Chinese non-smoker was diagnosed with epidermal growth factor receptor mutation-positive lung adenocarcinoma with cerebral metastases and commenced erlotinib. After 5 weeks, she presented with a 3-day history of severe bilateral facial weakness (House-Brackmann grade V/VI) and hypogeusia consistent with bilateral facial nerve palsies. MRI demonstrated new, symmetrical contrast-enhancing foci at the expected location of the facial nerves, consistent with leptomeningeal progression. Erlotinib was ceased and osimertinib was commenced. Facial nerve motor and sensory function began to improve within 1 week and by 2 weeks had returned to near normal. Review at 2 and 6 months d..

View full abstract

University of Melbourne Researchers